Announcement on Provision for Asset Impairment for 2025
Filed with SSE · · 3 pages · Chinese
Earlier from Sinotherapeutics
- Summary Announcement on 2025 Restricted Stock Incentive Plan (Revised Draft)
- Announcement on Voluntary Disclosure of Clinical Trial Applications for Eisaiconazole Sulfate for Injection Approved by China NMPA
- Announcement on Appointment of Senior Management Members
- Announcement on Postponement of Investment Projects Financed by Raised Funds
- Announcement on Voluntary Disclosure of the Renewal and Inclusion of the Company’s Product in the National Medical Insurance Catalog
Later from Sinotherapeutics
- Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares
- Announcement on Voluntary Disclosure of the Proposed Selection of Products in the National Continuation Drug Procurement
- Announcement on Preliminary Earnings Estimate for 2025
- Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company’s Vitamin K1 Tablets
- Announcement on Approval by Shanghai Municipal State-owned Assets Supervision and Administration Commission for Abstract of 2025 Restricted Stock Incentive Plan (Revised Draft)
Follow Sinotherapeutics into a list and get an email when it puts out news.
Follow Sinotherapeutics